Pfizer and BioNTech start late-stage study of lead Covid-19 shot

Pfizer and BioNTech said that they had selected a lead vaccine candidate from within a broader development programme and will proceed with a later-stage safety and efficacy trial of the experimental shot in a two-dose regimen
Pfizer and BioNTech SE said they’ve begun a later-stage trial for their top coronavirus vaccine candidate and set a goal of submitting it for regulatory review as soon as October — one of the most ambitious timelines to date.

 

The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc, which anno­unced earlier Monday that it had started its own large, final-stage trial of a shot based on similar technology.

 

Pfizer and BioNTech said that they had selected a lead vaccine candidate from within a broader development programme and will proceed with a later-stage safety and efficacy trial of the experimental shot in a two-dose regimen. The announcement came in anticipation of Pfizer reporting second-quarter earnings on Tuesday.

 

Governments around the world are now looking to lock up supplies of the still-experimental candidates.

 

Each has hopes of stabil­ising local economies and stopping spread of the virus that’s taken more than 650,000 lives globally. Last week, Pfizer and BioNTech clinc­hed a $2 billion deal to supply an initial 100 million doses of a vaccine to the US. That set a price ceiling of less than $20 per dose, which will likely impact how much others will charge.

           

 



Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel